CC-214-2 | m-entrepreneurship.com

Product Name :
CC-214-2

Search keywords :
CC214-2

drugId :
null

Target Vo:
Epidermal growth factor receptor variant III

Target Vo Short Name :
EGFRvIII

Moa_Name:
Anti-EGFRvIII

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Bristol-Myers Squibb Company

Active Company_Name :
Bristol-Myers Squibb Company

Active Indication_Name:
Glioblastoma

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
eIF4A1 Antibody (YA774)
SUMO1 Antibody (YA046)
Synaptophysin Antibody (YA664): Synaptophysin Antibody (YA664) is a non-conjugated and Mouse origined monoclonal antibody about 34 kDa, targeting to Synaptophysin (10C8). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts